Clinical Trials

Phase 2 Not yet recruiting

70 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06855225 2026-04-17

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

29 enrolled

Liver Neoplasms

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

535 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06880523 2026-04-14

SLIDE-HCC

140 enrolled

Carcinoma, Hepatocellular

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04034927 2026-04-13

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 2 Not yet recruiting

61 enrolled 15 charts

Gynecologic

Fallopian Tube Neoplasms

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

40 enrolled

Carcinoma, Hepatocellular

NCT06008093 2026-03-30

TRITON

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07489976 2026-03-27

IIT2025-03-YANG-LIFT-HCC

41 enrolled

Hepato Cellular Carcinoma

NCT03410615 2026-03-24

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

129 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03937830 2026-03-24

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

27 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03753919 2026-03-11

DUTHY

Phase 2 Terminated

79 enrolled 25 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01843374 2026-03-05

Tremelimumab

Other solid neoplasmThoracic

571 enrolled 19 charts

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT03057106 2026-03-03

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

301 enrolled 15 charts

Lung Cancer Metastatic

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

55 enrolled

Carcinoma, Hepatocellular

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

433 enrolled 26 charts

Carcinoma, Hepatocellular

NCT03965468 2026-02-09

CHESS

96 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04395079 2026-02-09

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

9 enrolled

Metastatic Malignant Female Reproductive System Neoplasm

NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

30 enrolled

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

39 enrolled